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a b s t r a c t
Background: Even with the use of a reduced energy setting (20–25 W), excessive transmural injury (ETI)
following catheter ablation of atrial ﬁbrillation (AF) is reported to develop in 10% of patients. However,
the incidence of ETI depends on the pulmonary vein isolation (PVI) method and its esophageal
temperature monitor setting. Data comparing the incidence of ETI following AF ablation with and
without esophageal temperature monitoring (ETM) are still lacking.
Methods: This study was comprised of 160 patients with AF (54% paroxysmal, mean: 24.072.9 kg/m2).
Eighty patients underwent ablation accompanied by ETM. The primary endpoint was deﬁned as the
occurrence of ETI assessed by endoscopy within 5 d after the AF ablation. The secondary endpoint was
deﬁned as AF recurrence after a single procedure. If the esophageal temperature probe registered
439 1C, the radiofrequency (RF) application was stopped immediately. RF applications could be
performed in a point-by-point manner for a maximum of 20 s and 20 W. ETI was deﬁned as any injury
that resulted from AF ablation, including esophageal injury or periesophageal nerve injury (peri-ENI).
Results: The incidence of esophageal injury was signiﬁcantly lower in patients whose AF ablation
included ETM compared with patients without ETM (0 [0%] vs. 6 [7.5%], p¼0.028), but not the incidence
of peri-ENI (2 [2.5%] vs. 3 [3.8%], p¼1.0). AF recurrence 12 months after the procedure was similar
between the groups (20 [25%] in the ETM group vs. 19 [24%] in the non-ETM group, p¼1.00).
Conclusions: Catheter ablation using ETM may reduce the incidence of esophageal injury without
increasing the incidence of AF recurrence but not the incidence of peri-ENI.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Pulmonary vein isolation (PVI) has become a standard therapy in
the management of atrial ﬁbrillation (AF) [1,2]. Although AF ablation is
widely considered safe, serious esophageal complications, such as
atrioesophageal ﬁstulae, esophageal erythema, esophageal ulcerations,
and periesophageal nerve injury (peri-ENI, e.g., acute pyloric spasms
and gastric hypomotility), occasionally occur [3–8]. These serious
esophageal complications may be caused by excessive damage beyond
the left atrial (LA) posterior wall during radiofrequency (RF) energy
deliveries. To avoid these complications, monitoring esophageal tem-
perature is recommended during RF applications to the LA posterior
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wall [9]. Halm et al. reported that lesions occurred in patients with an
esophageal temperature 441 1C, and for every 1 1C increase in
esophageal temperature, the odds of an esophageal lesion increased
by a factor of 1.36 (95% conﬁdence interval [CI]¼1.07–1.74; p¼0.012)
[10]. Yamasaki et al. reported that body mass index (BMI) (kg/m2) was
the only independent predictor of excessive transmural injury (ETI)
(odds ratio [OR]¼0.76; 95% CI 0.59–0.97; po0.05) [5]. Most recently,
we demonstrated that AF ablationwith a lower-energy setting of 20W
strictly controlled by esophageal temperature monitoring (ETM) at
39 1C could reduce the esophageal injury even in patients with a
BMIo24.9 kg/m2 [11]. As for the incidence of peri-ENI, Miyazaki et al.
reported that BMI was the only independent predictor for identifying
patients who would develop peri-ENI during RF applications to the LA
posterior wall with a relatively higher setting of 25–30W and a
duration of 30 s (OR¼0.77; 95% CI¼0.64–0.92; p¼0.0045) [12].
However, data comparing the incidence of ETI (including esophageal
injury and peri-ENI) following AF ablation with and without ETM are
still lacking. In the current study, we sought to investigate the safety
and effects of AF ablation strictly controlled by ETM in patients who
underwent PVI with a lower energy setting of 20W and a duration of
20 s for each RF application.
2. Material and methods
2.1. Patient characteristics
Patients (N¼160) with highly symptomatic, medically refractory
AF whowere treatedwith catheter ablationwith or without ETMwere
retrospectively analyzed. Of these, 80 patients underwent AF ablation
with ETM (the ETM group). During the same period, from a database
of 312 patients who underwent AF ablation without ETM, a computer
model created a control group of another 80 patients (controls; non-
ETM group) matched to the ETM group according to age, sex, type of
AF, and BMI. All procedures in both groups were performed in the
following centers: Himeji Cardiovascular Center, Tsukuba University,
and Kobe University. The baseline characteristics of the 2 groups are
shown in Table 1. Ethical approval was obtained from the institutional
review committees, and all patients in the ETM group gave their
informed written consent before participation. Every researcher
involved in this study acted in conformity with the Declaration of
Helsinki (adopted by the 18th World Medical Association General
Assembly, Helsinki, Finland in 1964).
2.2. Mapping and ablation procedure
Prior to the procedure, transesophageal echocardiography was
performed to exclude any thrombus formation. Patients were studied
under deep propofol sedation while breathing spontaneously. Stan-
dard electrode catheters were placed in the right ventricular apex
and coronary sinus, after which a single transseptal puncture was
performed. Unfractionated heparin was administered in a bolus form
before the transseptal puncture to maintain an activated clotting
time of 4300 s. If AF occurred, internal electrical cardioversion was
performed to restore sinus rhythm. Selective angiography of the
pulmonary veins and barium esophagography were performed.
After integration of a 3-dimensional (3D) model of the anatomy of
the LA and pulmonary veins (PVs) obtained from preinterventional
computed tomography (CT) or magnetic resonance imaging (MRI),
mapping and ablation were performed using the CARTO3 (Biosense
Webster Inc., Diamond Bar, CA, USA) or NavX (St. Jude Medical, Inc.,
St. Paul, MN) system as a guide. Prior to the ablation, the circular
mapping catheter (Lasso, Biosense Webster, Diamond Bar, CA;
Optima, St. Jude Medical Inc., St. Paul, MN, USA) and ablation
catheter–reconstructed LA posterior anatomies were aligned with
the CT or MRI image [13–15]. Image integration was ﬁnely adjusted
using 3 additional landmarks (top of the left superior PV [LSPV], right
superior PV [RSPV], and bottom of the left inferior PV [LIPV]), and the
tip of the ablation catheter (ThermoCool, Biosense Webster; IBI
Therapy Cool Flex, St. Jude Medical, Inc.) was positioned at the
landmarks based on ﬂuoroscopic and electrographic information.
RF alternating current was delivered in unipolar mode between the
irrigated-tip electrode of the ablation catheter and an external back-
plate electrode. The initial RF generator setting consisted of an upper
catheter tip temperature of 43 1C, maximal RF power of 30W, and
irrigation ﬂow rate of 17 or 13 mL/min using the CARTO3 and NavX
systems, respectively. In patients requiring RF applications to the
posterior wall, the initial RF generator setting consisted of a maximal
RF power of 20W. All patients underwent extensive encircling
pulmonary vein isolation [16]. RF applications were performed in a
point-by-point manner. The maximum time spent at the anterior and
posterior walls was 40 s and 20 s, respectively. The encircling ablation
line was created approximately 0.5–1 cm from the PV ostia. In the
ETM group, the RF energy was routinely reduced by 10W when
ablating the posterior wall, based on the esophageal temperature
measured with an esophageal temperature probe (SensiTherm, St.
Jude Medical) [17]. If the esophageal temperature rose to 439 1C, the
ablation was stopped immediately and the energy was further
reduced. After the esophageal temperature decreased to the normal
range (37 1C), the RF application was resumed. If ablation could not be
performed with 20-W energy, the line placement was performed
either more antral or closer to the PV, depending on the patient's
anatomical characteristics (Fig. 1) [18]. The RF energy setting for the
posterior wall far from the esophagus was 25W for a duration of 30 s.
In the non-ETM group, the RF energy for the LA posterior wall was
titrated to 20W with an RF duration of 20 s at the Himeji Cardiovas-
cular Center and Kobe University, and to 20W for 30 s at Tsukuba
University. Furthermore, a450-s break was applied between each RF
energy application at Tsukuba University. Catheter navigation was
performed with a nonsteerable sheath (Prefaces, Biosense Webster)
or a steerable sheath (Agilis, St. Jude Medical Inc.).
The procedural endpoint was electrophysiologically proven
bidirectional block of the PV-encircling ablation lines, conﬁrmed
with a circular mapping catheter. After proving bidirectional block
of the PVs, we performed a stimulation protocol (burst pacing from
the coronary sinus at 300 ms, 250 ms, and 200 ms for 10 s each) to
test the inducibility of AF. When AF was induced, additional
ablation consisting of linear ablation at the LA roof and/or a bottom
line connecting the bottom of the inferior PVs was performed. A
pharmacological test consisting of high-dose isoproterenol infusion
(20 mg/min) was performed to identify non-PV triggers. Ablation of
the cavotricuspid isthmus was performed only if typical right atrial
ﬂutter was either documented previously or induced by burst
pacing at the end of the procedure. Patients were started on proton
pump inhibitors on admission and continued for 4 weeks at the
Himeji Cardiovascular Center and Kobe University, and for 2 weeks
Table 1
Baseline characteristics of the 2 patient groups.
ETM group Non-ETM group p Value
Sex (male) (n, %) 60 (75) 65 (81) 0.45
Age (years) 60.778.2 58.2710.6 0.10
Paroxysmal AF (n, %) 45 (56) 41 (51) 0.63
AF history (month) 36 (12; 72) 36 (12; 66) 0.78
Hypertension (n, %) 44 (55) 31 (39) 0.06
Structural heart disease (n, %) 11 (14) 19 (24) 0.16
Diabetes mellitus (n, %) 8 (10) 11 (14) 0.63
Left atrial diameter (mm) 41.376.3 39.276.7 0.05
LVEF (%) 61.778.3 64.078.6 0.09
BMI (kg/m2) 23.973.1 23.973.0 0.92
ETM¼esophageal temperature monitoring, AF¼atrial ﬁbrillation, LVEF¼ left ven-
tricular ejection fraction, BMI¼body mass index.
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at Tsukuba University. Esophagoscopy was repeated after 3–4 d if
mucosal ulcerations 410 mm were observed initially [10].
2.3. Assessment of the esophageal course
Before the RF applications to the LA posterior wall, PV and left
atrium (PV–LA) angiography and esophagography were performed
during high-rate right ventricular pacing of 200 ppm and sinus rhythm,
respectively (Fig. 2). The course of the esophagus was categorized into
3 columns: column 1 indicated the left-sided area of the posterior wall
from the left antral portion, column 3 indicated the right-sided area of
the posterior wall from the right antral portion, and column 2 indicated
the middle area between columns 1 and 3 (Fig. 2A).
2.4. Esophageal and gastric endoscopy after AF ablation
Esophageal and gastric endoscopy was performed 1–5 d after
ablation for AF in all patients. ETI was deﬁned as any esophageal
injury resulting from RF energy applications, including esophageal
erythema, necrotic ulcerations, atrioesophageal ﬁstulae, acute pyloric
spasms, or peri-ENI [5,12]. Patients were diagnosed as having peri-ENI
if they exhibited the following symptoms and ﬁndings after AF
ablation: acute onset of characteristic prolonged symptoms of gastric
delayed emptying, such as nausea, vomiting, postprandial fullness,
bloating, constipation, or epigastric pain and the ﬁnding of gastric
hypomotility assessed by abdominal X-ray and CT. ETI was assessed
and diagnosed by independent, experienced gastroenterologists
blinded to the patients' characteristics and ablation procedures [12].
2.5. Follow-up
Antiarrhythmia treatment was discontinued postintervention-
ally, and beta-blockers were administered to all patients. After
treatment, patients were administered oral anticoagulants for Z6
months (target international normalized ratio: 2.0–3.0), depend-
ing on their individual stroke risk based on the CHADS2 score. In
Fig. 1. Radiofrequency applications to the LAPW strictly controlled by ETM. (A) Esophageal temperature monitoring during RF applications. The 3D yellow and red tags indicate
ablation points with and without an esophageal temperature rise of 439 1C, respectively (left panel). The 3D green tags indicate the ablation points achieving bidirectional
block between the LA and PV. Of note, the esophageal temperature increased to 40.7 1C even though the RF applications were terminated immediately after esophageal
temperature rose to 439 1C (right panel). (B) A representative case of esophageal temperature rise. Even with RF applications delivered with a reduced energy of 20W,
esophageal temperature increased to 39 1C nine seconds after RF application. Despite the cessation of the RF application, the esophageal temperature continued to increase to
41.3 1C. LAPW¼ left atrial posterior wall, RF¼radiofrequency, LA¼ left atrium, PV¼pulmonary vein.
Fig. 2. PV–LA angiography and esophagography during the procedure. (A) PV–LA angiography during high-rate right ventricular pacing (anteroposterior view). We classiﬁed
the LAPW into 3 segments: left-sided area, right-sided area, and middle area. (B) Esophagography in the same patient. Of note, the esophagus was located in the left-sided
area of the LAPW (anteroposterior view). PV¼pulmonary vein, LA¼ left atrium, LAPW¼ left atrial posterior wall.
K. Kiuchi et al. / Journal of Arrhythmia 32 (2016) 36–4138
all patients, 24-h Holter electrocardiography (SCM-6600, Fukuda
Denshi, Tokyo, Japan) was performed after 3 and 6 months. If
symptoms occurred outside of the recording period, patients were
requested to contact our center or the referring physician to obtain
electrocardiographic documentation. AF and/or macroreentrant
atrial tachycardia episodes lasting 430 s were considered recur-
rences [19].
2.6. Statistics
Data assessed using the Kolmogorov–Smirnov test are pre-
sented as the mean7standard deviation for normally distributed
variables. Median and quartile values are given for nonnormally
distributed variables. Categorical variables are expressed as the
number and percentage of patients. Continuous and categorical
variables between the 2 groups were analyzed using Student's t
test and Fisher's exact test, respectively. If the distribution was
skewed, the data were compared using the Mann–Whitney U test.
Differences were considered statistically signiﬁcant if po0.05. All
statistical analyses were performed with IBM SPSS Statistics
version 17.0 (IBM Inc., Chicago, IL, USA).
3. Results
3.1. Patient characteristics
Patient characteristics are displayed in Table 1. The 2 groups were
electronically matched in a 1-to-1 ratio according to age, sex, type of
AF, and BMI. There were no signiﬁcant differences in AF history and left
ventricular ejection fraction (LVEF) between the 2 groups (AF history
(months)¼56 [12;72] vs. 56 [12;66]; p¼0.78; LVEF (%)¼61.778.3 vs.
64.078.6; p¼0.09). The groups were comparable with the exception
of the left atrial diameter (41.376.3 mm vs. 39.276.7 mm in the ETM
and non-ETM groups, respectively, p¼0.05).
3.2. Course of the esophagus and procedural parameters
In the majority of patients, the esophageal course assessed by
esophagography was in the left-sided LA posterior wall (LAPW).
Esophageal course was in the left-sided area, middle area, and
right-sided LAPW in 61 (76%), 10 (13%), and 9 (11%) patients in the
ETM group, and in 69 (86%), 8 (10%), and 3(4%) patients in the non-
ETM group respectively. The distribution of esophageal courses did
not differ between the 2 groups (p¼0.16) (Table 2).
The procedural parameters included procedure time, additional
ablation with or without a superior vena cava isolation, linear
ablation, and complex fractionated atrial electrogram ablation. In
all these parameters, the groups were comparable, with the excep-
tion of the use of a steerable sheath (49 [61%] vs. 4 [5%] in the ETM
and non-ETM groups, respectively; po0.001) (Table 2). In the ETM
group, esophageal temperature reached 39 1C during a mean number
of 3.272.2 RF applications; the mean duration of RF applications
when esophageal temperature reached 439 1C was 1373 s, and the
maximal esophageal temperature was 40.570.6 1C.
3.3. Incidence of ETI and AF recurrence in the ETM and non-ETM
groups
The incidence of ETI was lower in the ETM than in the non-ETM
group (2 [3%] vs. 9 [11%] patients, respectively; p¼0.06). Com-
pared with catheter ablation without using ETM, catheter ablation
with ETM signiﬁcantly reduced the incidence of esophageal injury
from 7.5% to 0% (p¼0.03). However, the incidence of peri-ENI was
comparable between the 2 groups (2 [2.5%] in the ETM group vs. 3
[3.8%] in the non-ETM group; p¼1.00) (Table 3). AF recurrence at
12 months after a single ablation procedure was also comparable
for both groups (20 [25%] in the ETM group vs. 19 [24%] in the non-
ETM group; p¼1.00) (Table 3). A second AF ablation session was
performed in 15 (75%) of 20 patients with AF recurrence in the
ETM group. A total of 33 reconduction sites were detected. Of
those, only 6 sites were located on the esophageal course: 1 in the
posterior wall of LSPV, 3 in the carina posterior, and 2 in the
posterior wall of the LIPV. The remaining 27 sites were as follows:
5 in the roof at the LSPV, 5 in the carina between the LSPV and
LIPV, 4 in the anterior ridge of the LSPV, 3 in the bottom of the
LIPV, 5 in the roof at the RSPV, 3 in the carina between the RSPV
and RIPV, and 2 in the bottom of the RIPV. The reconduction sites
were likely distributed equally around the PV circular lesion. A
multivariable logistic regression analysis model was applied to
deﬁne predictors of the incidence of peri-ENI. After performing
this analysis, BMI was associated with a higher risk of peri-ENI
(OR¼0.56; 95% CI¼0.52–0.98; p¼0.04). Patient age, sex, type of
AF, AF history, left atrial diameter (LAD), LVEF, and use of a
steerable sheath were not associated with peri-ENI (Table 4).
However, the maximal esophageal temperature and number of
times esophageal temperature reached 439 1C were probably
higher in 2 patients with peri-ENI in the ETM group (patient 1:
41.6 1C, 6RF applications with temperature rise to 439 1C;
patient 2: 41.9 1C, 9RF applications with temperature rise to
439 1C). Of interest, frequent RF applications at the posterior wall
of the LIPV were performed in such patients.
4. Discussion
4.1. Main ﬁndings
The results of this study demonstrated that ETM-guided AF
ablation at a 39 1C setting signiﬁcantly reduced the incidence of
esophageal injury without elevating the risk of AF recurrence.
However, the incidence of peri-ENI could not be reduced by using
ETM. A lower BMI was associated with a higher incidence of peri-
Table 2
Esophageal course and procedural parameters in the 2 patient groups.
ETM group Non-ETM group p Value
Esophageal course 0.16
Left-sided area (n, %) 61 (76) 69 (86)
Middle area (n, %) 10 (13) 8 (10)
Right-sided area (n, %) 9 (11) 3 (4)
Procedural parameters
Procedure time (min) 264759 242791 0.14
Usage of a steerable sheath (n, %) 49 (61) 4 (5) o0.001
SVC isolation (n, %) 8 (10) 4 (5) 0.37
Box lesion (n, %) 6 (8) 9 (11) 0.59
Mitral isthmus ablation (n, %) 3 (6) 5 (6) 0.72
CFAE ablation (n, %) 8 (10) 8 (10) 1.00
ETM¼esophageal temperature monitoring, SVC¼superior vena cava, CFAE¼complex
fractionated atrial electrogram.
Table 3
Incidence of ETI and AF recurrence in the 2 patient groups.
ETM group Non-ETM group p Value
ETI (n, %) 2 (3) 9 (11) 0.06
Esophageal injury (n, %) 0 (0) 6 (7,5) 0.03
Periesophageal nerve injury (n, %) 2 (3) 3 (4) 1.00
AF recurrence (n, %) 20 (25) 19 (24) 1.00
ETI¼excessive thermal injury, AF¼atrial ﬁbrillation.
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ENI. Other preprocedural and procedural parameters, including
age, sex, type of AF, AF history, LAD, LVEF, and use of a steerable
sheath were not associated with peri-ENI.
4.2. Impact of ETM-guided AF ablation on reducing the incidence of
esophageal injury
We previously reported on the prevalence and characteristics of
asymptomatic ETI after AF ablation that used lower-energy applica-
tion of 20W to the LAPW, but without ETM. Yamasaki et al.
demonstrated that ETI occurred in 10 (9.6%) of 104 patients, all of
whomwere asymptomatic: esophageal injury occurred in 4 patients,
and peri-ENI occurred in 6. All patients who developed ETI were
below normal weight (BMIo24.9 kg/m2). In our multivariable logis-
tic analysis, we demonstrated that the only independent predictor of
ETI was BMI (OR¼0.76; 95% CI¼0.59–0.97; po0.05) [5]. Further-
more, we reported the incidence of esophageal injury after ETM-
guided AF ablation in patients with a small BMI [11]. No esophageal
injury was observed in any patients in that study. Halm et al.
reported that the maximal temperature in the esophagus was
signiﬁcantly higher in patients with esophageal injury than in
patients without injury [10]. Of interest, esophageal injury did not
occur below an intraluminal esophageal temperature of 41 1C. As for
the ETM, Kuwahara et al. reported gradual increases in esophageal
temperatures after the cessation of RF energy applications and found
that increases of 1–3 1C within 10–20 s of RF energy cessation were
common before temperatures returned to control levels [20]. There-
fore, we considered that ceasing RF energy at 39 1C should be ideal to
prevent reaching the maximum esophageal temperature of 41 1C. In
our study, the maximal esophageal temperatures of 441 1C and
441.5 1C were documented in 8 (10%) and 1 (1.3%) patients in the
ETM and non-ETM groups, respectively. Fortunately, no esophageal
injury was documented in those patients. We speculated that RF
application, even with a reduced power setting of 20W, could
increase esophageal temperature to 441 1C in patients with a
lower BMI.
4.3. Limitations of ETM-guided AF ablation for reducing the
incidence of peri-ENI
In contrast to esophageal injury, the incidence of peri-ENI was
not reduced by using ETM-guided AF ablation. Kuwahara et al.
reported that the clinical course and severity of peri-ENI vary, but
most patients ultimately recover with conservative treatment. In
their study, peri-ENI occurred in 4 of 157 (2.5%) patients whose
ablation procedure did not use ETM, and 7 of 3538 (0.2%) patients
who did have ETM during ablation [21]. Furthermore, Kuwahara
et al. suggested the possibility of reducing both the incidence and
severity of peri-ENI by applying RF under ETM guidance [22].
Recently, Miyazaki et al. reported on factors associated with peri-
ENI after AF ablation. They demonstrated that peri-ENI was a more
common form of collateral damage than direct esophageal injury,
and that BMI was an independent periprocedural predictor of the
incidence of peri-ENI after AF ablation. Of note, Miyazaki et al.
suggested that no peri-ENI was observed after AF ablation, regard-
less of patient BMI, under a power titration regimen in a speciﬁc,
small area of the posterior LA where the ablation line transversed
the esophagus. They emphasized both the need to recognize this
unnoticeable complication and the importance of titrating energy at
that speciﬁc area while taking BMI into account in AF ablation
procedures [12]. In the current study, peri-ENI occurred in 2 (2.5%)
patients in the ETM group and 3 (3.8%) patients in the non-ETM.
The current power setting of RF applications to the LAPW was
reduced to 20W in all patients in both the ETM and non-ETM
groups. Therefore, we speculated that discrepancies in outcomes
were caused by the following: (1) patients with a signiﬁcantly lower
BMI, (2) the use of steerable sheaths, and (3) an additional ablation
line. The mean BMI in patients with peri-ENI was 2270.1 kg/m2. RF
applications to the LAPW with a steerable sheath were performed
in 49 (61%) patients in the ETM group. Of interest, additional
ablation with a roof line including a box lesion was performed in
4 (80%) of 5 patients with peri-ENI. The vagus nerve bifurcates the
anterior and posterior portions of the periesophageal nerve at the
roof level of the left atrium and forms the plexus. The plexus was
widely located on the anterior and posterior wall of the esophagus
and converged with the anterior and posterior vagal trunks, which
control gastric peristalsis, the pyloric sphincter, and gastric motility,
at the bottom level of the LA. Considering this anatomical localiza-
tion of the vagal nerve, including the periesophageal nerve, a single
RF application at the vagal trunk, which was located at the roof and/
or bottom line near the esophagus, could have caused peri-ENI,
even with a maximum esophageal temperature of o41 1C. This
theory is consistent with our results in patients in the ETM group
who developed peri-ENI.
4.4. AF recurrence and procedure time in ETM-guided AF ablation
In this study, AF recurrence at 12 months after the single ablation
procedure did not differ between the 2 groups. ETM-guided AF
ablation was able to reduce the incidence of esophageal injury
without increasing the risk of AF recurrence. To prevent esophageal
injury, prolonging the procedure time r10% is considered acceptable.
AF ablation with a steerable sheath is reported to improve the quality
of the PVI and rhythm outcome owing to improved contact force.
Although many studies have reported on the incidence of esophageal
injury in ablation procedures, the ablation strategy used (e.g., with or
without a steerable sheath, temperature setting guided by ETM or
not, and RF power settings) varied among reports. A previous study
that used an ablation style similar to ours (using a steerable sheath
and ETM) demonstrated that the incidence of esophageal injury and
peri-ENI was 11%, much higher than our results [15–17,23]. Consider-
ing the details of the ablation settings, a difference in ETM setting
could have caused these differences. An ETM setting of 39 1C was
considered acceptable for preventing a maximal esophageal tempera-
ture of 441 1C and for providing safe RF application with a steerable
sheath, especially in patients with a lower BMI.
4.5. Study limitations
Our study had 3 major limitations. First, the sample size was
relatively small. Second, the control cases were recruited from
2 different centers, between which the operator's experience and
ablation technique may have varied. However, the concept of an
ablation strategy including extensive encircling pulmonary vein
isolation was the same, and the RF power settings for the LAPW
and esophagography for preventing esophageal injury were
Table 4
Predictors of the incidence of peri-ENI based on a multivariable logistic regression
analysis.
Adjusted HR 95% CI p Value
Age 0.98 0.86–1.12 0.77
Female sex 1.73 0.12–24.8 0.69
BMI (kg/m2) 0.56 0.32–0.98 0.04
Type of AF 6.70 0.58–77.4 0.13
AF history, months 1.01 0.99–1.03 0.27
LAD, mm 1.20 0.99–1.16 0.63
LVEF, % 1.03 0.92–1.14 0.63
Use of a steerable sheath 1.67 0.16–18.1 0.67
HR¼hazard ratio, BMI¼body mass index, AF¼atrial ﬁbrillation, LAD¼ left atrial
diameter, LVEF¼ left ventricular ejection fraction.
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performed in the same manner. Third, this study was a nonrando-
mized, case–control study with many inherent drawbacks. Its retro-
spective design makes it prone to bias. The patients in the ETM group
were enrolled from the Himeji Cardiovascular Center and Kobe
University. Patients in the non-ETM group were enrolled from
Tsukuba University. Therefore, the use of steerable sheaths differed
between the groups. As for the efﬁcacy of RF applications, the use of
steerable sheaths was reported to provide more contact force and
durable RF lesions without gaps, thereby reducing AF recurrence. As
for the safety of RF applications, AF ablation using steerable sheaths
made it easier to control the contact force and the ablation site
compared with AF ablation without steerable sheaths. Therefore, the
use of steerable sheaths may have affected the impact of ETM.
Esophageal and gastric endoscopy both before and after AF
ablation could not be performed. Therefore, we could not conﬁrm
whether the esophageal erythema was caused by transesophageal
echocardiography before AF ablation or RF energy application.
However, the impact of ETM in reducing the incidence of esopha-
geal injury was evident. Ethically, it may be difﬁcult to verify our
ﬁndings in a randomized prospective study.
5. Conclusion
Catheter ablation using ETMmay be able to reduce the incidence
of esophageal injury without elevating the risk of AF recurrence, but
it did not reduce the incidence of peri-ENI. To completely prevent
ETI, a more careful ablation procedure should be performed in
patients with a small BMI, even if ETM is used for guidance.
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